Want to see MDCX full AI Analyst Report?

Medicus Pharma Ltd (MDCX) Price & Analysis

306 Followers

MDCX Stock Chart & Stats

$1.46

-$0.29(-9.70%)

At close: Jan 08 4:00 PM EST

$1.46

-$0.29(-9.70%)

Day’s Range― - ―

52-Week Range$0.25 - $3.44

Previous CloseN/A

Volume5.92K

Average Volume (3M)2.44M

Market Cap

$24.28M

Enterprise Value$1.56M

Total Cash (Recent Filing)$6.37M

Total Debt (Recent Filing)$169.62K

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Aug 20, 2026

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.20

Shares Outstanding56,658,165

10 Day Avg. Volume1,217,921

30 Day Avg. Volume2,439,630

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)-391.45

Price to Sales (P/S)0.00

P/FCF Ratio-1.16

Enterprise Value/Market Cap0.06

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.04

Forecast

1Y Price Target

$5.50

Price Target Upside276.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.51

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Progress: Rare Pediatric Designation FilingFiling for Rare Pediatric Disease Designation is a structural regulatory milestone that can expedite development pathways and unlock incentives (e.g., priority review or vouchers). This advances SkinJect toward a clearer approval path and improves program de-risking over the next months.

Advancing Teverelix Toward Registrational Phase 2bA formal EU CTIS submission for a Phase 2b registrational-focused study reflects strategic progression from exploratory to registrational development. This structural step refines dose/PK/PD data and strengthens the program’s regulatory dossier for future approval-enabling trials.

Modest Reported Leverage And Asset GrowthCurrent reported leverage is low on a TTM basis, and asset growth signals capacity to build program infrastructure. Modest leverage reduces short-term solvency risk and, when combined with capital access, supports continued clinical execution over the medium term.

Bears Say

Pre-revenue With Widening LossesThe company remains pre-revenue while operating losses have expanded materially. Persistent negative earnings reflect no internal revenue runway and create ongoing pressure to fund development externally, increasing long-term dilution and execution risk if trials delay.

Large, Sustained Cash Burn And Negative FCFSubstantial negative operating and free cash flow indicate the company cannot self-fund development. This structural cash burn necessitates repeated external financing, constrains strategic choices, and elevates the probability of dilution or compromised program timelines.

Nasdaq Non-compliance And Dilutive Funding RelianceAn active Nasdaq non-compliance notice plus expansion of ATM capacity signals structural listing and liquidity pressure. Management faces persistent incentive to raise equity, increasing dilution risk and potentially impairing investor confidence and long-term capital access.

Medicus Pharma Ltd News

Medicus submits SkinJect Rare Pediatric Disease Designation request to FDA

Medicus Pharma (MDCX) announced the submission of a Rare Pediatric Disease Designation request to the FDA for SkinJect,...

26d ago

MDCX

Medicus Pharma submits substantial modification application through EU CTIS

Medicus Pharma (MDCX) announced the submission of a substantial modification application through the European Union Clinical Trials Information...

1M ago

MDCX

Medicus Pharma Shareholders Approve Auditor, Board and Consolidation

An update from Medicus Pharma Ltd ( ($MDCX) ) is now available. On June 3, 2026, Medicus Pharma...

1M ago

MDCX

Medicus Pharma submits Protocol SKNJCT-005 to the FDA

Medicus Pharma (MDCX) announced the submission of Protocol SKNJCT-005 to the FDA under the company’s existing investigational new...

1M ago

MDCX

Medicus Pharma Secures Financing Amid Nasdaq Compliance Pressure

An announcement from Medicus Pharma Ltd ( ($MDCX) ) is now available. On May 27, 2026, Medicus Pharma...

1M ago

MDCX

Medicus Pharma reports Q1 EPS (31c), consensus (22c)

“During the first quarter of 2026, Medicus continued to execute on its transformation into a diversified clinical-stage biotechnology...

2M ago

MDCX

Medicus Pharma announces results from Phase 2 SKNJCT-003 analysis

Medicus Pharma (MDCX) announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase...

2M ago

MDCX

Medicus Pharma meets with lawmakers to support SkinJect designations

Medicus Pharma (MDCX) announced that CEO Raza Bokhari, along with the Medicus leadership team, conducted a series of...

2M ago

MDCX

Balancing Pipeline Potential and Funding Risk: Justifying a Buy Rating on Medicus Despite Extended Timelines

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Medicus Pharma Ltd. The associated price...

3M ago

MDCX

Medicus Pharma Expands ATM Equity Program for Funding

Medicus Pharma Ltd ( ($MDCX) ) has provided an announcement. On April 23, 2026, Medicus Pharma Ltd. amended...

3M ago

MDCX

Medicus Pharma initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $9 price target The firm...

3M ago

MDCX

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

Medicus Pharma (MDCX) announced the submission of an Orphan Drug Designation, ODD, application to the U.S. Food and...

3M ago

MDCX

Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy

Medicus Pharma Ltd ( ($MDCX) ) has shared an announcement. Medicus Pharma will present new Phase I data...

3M ago

MDCX

Medicus Pharma enters media partnership with New to The Street

Medicus Pharma (MDCX) entered into a 12-part, one-year strategic media agreement with New to The Street to expand...

3M ago

MDCX

MDCX FAQ

What was Medicus Pharma Ltd’s price range in the past 12 months?

Medicus Pharma Ltd lowest stock price was $0.25 and its highest was $3.44 in the past 12 months.

What is Medicus Pharma Ltd’s market cap?

Medicus Pharma Ltd’s market cap is $24.28M.

When is Medicus Pharma Ltd’s upcoming earnings report date?

Medicus Pharma Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 40 days.

How were Medicus Pharma Ltd’s earnings last quarter?

Medicus Pharma Ltd released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.118.

Is Medicus Pharma Ltd overvalued?

According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicus Pharma Ltd pay dividends?

Medicus Pharma Ltd does not currently pay dividends.

What is Medicus Pharma Ltd’s EPS estimate?

Medicus Pharma Ltd’s EPS estimate is -0.13.

How many shares outstanding does Medicus Pharma Ltd have?

Medicus Pharma Ltd has 56,658,165 shares outstanding.

What happened to Medicus Pharma Ltd’s price movement after its last earnings report?

Medicus Pharma Ltd reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -10.682%.

Which hedge fund is a major shareholder of Medicus Pharma Ltd?

Currently, no hedge funds are holding shares in MDCX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicus Pharma Ltd

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Medicus Pharma Ltd (MDCX) Earnings & Revenues

Historic Earnings Reports

MDCX Stock 12 Month Forecast

Average Price Target

$5.50

▲(276.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$5.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,1.0615384615384615,1.7230769230769232,2.3846153846153846,3.046153846153846,3.7076923076923074,4.36923076923077,5.030769230769231,5.6923076923076925,6.353846153846154,7.015384615384615,7.676923076923077,8.338461538461539,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.7923076923076924,1.1846153846153846,1.576923076923077,1.9692307692307693,2.3615384615384616,2.753846153846154,3.146153846153846,3.5384615384615383,3.9307692307692306,4.323076923076923,4.7153846153846155,5.107692307692308,{"y":5.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.4,0.5230769230769231,0.6461538461538462,0.7692307692307693,0.8923076923076924,1.0153846153846153,1.1384615384615384,1.2615384615384615,1.3846153846153846,1.5076923076923077,1.6307692307692307,1.7538461538461538,1.876923076923077,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.285,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.348,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >